Table 4.
Placebo Group n = 22 |
Vitamin D Group n = 21 |
p Value | ||
---|---|---|---|---|
Ordinal Scale for clinical improvement by severity * at baseline (Day 1) | 0.512 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 0 (0.0) | 0 (0.0) | |
Moderate | n (%) | 21 (95) | 20 (95) | |
Severe | n (%) | 1 (4.5) | 1 (4.8) | |
Death | n (%) | 0 (0.0) | 0 (0.0) | |
Ordinal Scale for clinical improvement by severity * at Day 7 | 0.005 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 4 (18) | 15 (71) | |
Moderate | n (%) | 14 (63) | 4 (19) | |
Severe | n (%) | 3 (13) | 1 (4.8) | |
Death | n (%) | 1 (4.5) | 1 (4.8) | |
Ordinal Scale for clinical improvement by severity * at Day 15 | 0.549 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 15 (68) | 18 (85) | |
Moderate | n (%) | 4 (18) | 1 (4.8) | |
Severe | n (%) | 1 (4.5) | 1 (4.8) | |
Death | n (%) | 1 (4.5) | 1 (4.8) | |
Ordinal Scale for clinical improvement by severity * at Day 22 | 0.543 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 17 (77) | 19 (90) | |
Moderate | n (%) | 1 (4.5) | 0 (0.0) | |
Severe | n (%) | 2 (9.1) | 0 (0.0) | |
Death | n (%) | 2 (9.1) | 2 (9.5) | |
Ordinal Scale for clinical improvement by severity * at Day 29 | 0.543 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 17 (77) | 19 (90) | |
Moderate | n (%) | 1 (4.5) | 0 (0.0) | |
Severe | n (%) | 2 (9.1) | 0 (0.0) | |
Death | n (%) | 2 (9.1) | 2 (9.5) | |
Ordinal Scale for clinical improvement by severity * at Day 36 | 0.318 | |||
No infection | n (%) | 0 (0.0) | 0 (0.0) | |
Mild | n (%) | 17 (77.) | 19 (90) | |
Moderate | n (%) | 2 (9.1) | 0 (0.0) | |
Severe | n (%) | 0 (0.0) | 0 (0.0) | |
Death | n (%) | 3 (14) | 2 (9.5) |
* No infection = 0; Mild = Score 1, 2; Moderate = Score 3, 4, Severe = Score 5, 6, 7 and Death = Score 8.